Detailansicht

Wissensnetz

Person

Peter R. Galle (1957-)

Arzt

Name	Peter R. Galle
Zeit	1957- (Lebensdaten)
Ort	Heidelberg (Geburtsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med. (Universität Marburg) (1985)
Beruf	Arzt (charakteristischer Beruf)
Variante	Peter Robert Galle Peter Galle
Beziehung	Medizinische Klinik und Poliklinik 1 (Mainz) (1998-) Ludolf-Krehl-Klinik (1988-1998) Universität Heidelberg. Zentrum für Molekulare Biologie (1986-1988)
Weitere Angaben	Universitätsmedizin Mainz der Johannes Gutenberg Universität Mainz
Datensatztyp	Person
GND-Nummer	1111061963
Datensatz-ID	1111061963
Beteiligt an alle anzeigen Checkliste Gastroenterologie und Hepatologie Checkliste Gastroenterologie und Hepatologie Checkliste Gastroenterologie und Hepatologie Different risk and protective factors predict change of planning ability in middle versus older age Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones Aktuelle Behandlungsstrategien beim hepatozellulären Karzinom (HCC) : leitliniengerechte Diagnostik und Therapie, Erkenntnisse aus Real-World-Registern, neue Therapiestrategien How do (false) positively screened patients experience a screening programme for liver cirrhosis or fibrosis in Germany? A qualitative study Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study Acquired resistance to antiangiogenic therapies in hepatocellular carcinoma is mediated by yes‐associated protein 1 activation and transient expansion of stem‐like cancer cells Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis BAX re-distribution induces apoptosis resistance and selective stress sensitivity in human HCC Referenz Gastroenterologie Referenz Gastroenterologie Referenz Gastroenterologie Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial Induktion von replikativer DNS-Synthese in der primären Rattenleberzellkultur mit epidermalem Wachstumsfaktor, Cyproteronazetat und portalem Rattenserum Kompendium der Unfallchirurgie

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Peter R. Galle (1957-)

Checkliste Gastroenterologie und Hepatologie

Checkliste Gastroenterologie und Hepatologie

Checkliste Gastroenterologie und Hepatologie

Different risk and protective factors predict change of planning ability in middle versus older age

Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones

Aktuelle Behandlungsstrategien beim hepatozellulären Karzinom (HCC) : leitliniengerechte Diagnostik und Therapie, Erkenntnisse aus Real-World-Registern, neue Therapiestrategien

How do (false) positively screened patients experience a screening programme for liver cirrhosis or fibrosis in Germany? A qualitative study

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis

IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

Acquired resistance to antiangiogenic therapies in hepatocellular carcinoma is mediated by yes‐associated protein 1 activation and transient expansion of stem‐like cancer cells

Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis

BAX re-distribution induces apoptosis resistance and selective stress sensitivity in human HCC

Referenz Gastroenterologie

Referenz Gastroenterologie

Referenz Gastroenterologie

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Induktion von replikativer DNS-Synthese in der primären Rattenleberzellkultur mit epidermalem Wachstumsfaktor, Cyproteronazetat und portalem Rattenserum

Kompendium der Unfallchirurgie